Holen Sie sich die Stockscreener-App
4.984
3.67%
-0.156
Schlusskurs vom Vortag:
$5.14
Offen:
$5.14
24-Stunden-Volumen:
702.64K
Relative Volume:
0.19
Marktkapitalisierung:
$1.37B
Einnahmen:
$8.10M
Nettoeinkommen (Verlust:
$-92.72M
KGV:
-13.96
EPS:
-0.3571
Netto-Cashflow:
$-82.52M
1W Leistung:
-5.69%
1M Leistung:
-6.76%
6M Leistung:
+94.93%
1J Leistung:
+156.54%
1-Tages-Spanne:
$4.93
$5.19
1-Wochen-Bereich:
$4.80
$5.69
52-Wochen-Spanne:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Vergleichen Sie TSHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
5.00 | 1.41B | 8.10M | -92.72M | -82.52M | -0.3571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.19 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.84 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
815.91 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.19 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-11 | Eingeleitet | BofA Securities | Buy |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
Is Taysha Gene Therapies Inc. stock vulnerable to regulatory risks2025 Technical Patterns & Fast Exit and Entry Strategy Plans - ulpravda.ru
Is Taysha Gene Therapies Inc. stock a bargain at current levelsJuly 2025 Summary & Verified Chart Pattern Signals - ulpravda.ru
Can Taysha Gene Therapies Inc. stock beat analyst upgradesMarket Performance Report & High Conviction Buy Zone Alerts - ulpravda.ru
Can Taysha Gene Therapies Inc. stock rebound after recent weaknessJuly 2025 PreEarnings & Smart Money Movement Alerts - ulpravda.ru
Should I hold or sell Taysha Gene Therapies Inc. stock in 2025July 2025 Action & Reliable Entry Point Alerts - ulpravda.ru
Will Taysha Gene Therapies Inc. stock benefit from green energy trendsJuly 2025 Recap & Low Risk High Win Rate Picks - ulpravda.ru
Chardan Capital Maintains Buy Rating on TSHA at $12 | TSHA Stock News - GuruFocus
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Taysha doses first patient in pivotal Rett syndrome gene therapy trial - Investing.com Australia
Taysha Gene Therapies (TSHA) Advances in Rett Syndrome Gene Ther - GuruFocus
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome - The Manila Times
New gene therapy trial progresses for children and adults with Rett syndrome - Stock Titan
Taysha Gene Therapies, Inc.Common Stock (NQ: TSHA - FinancialContent
Wells Fargo Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Cuts Target Price to $11 - 富途牛牛
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Cut to "Sell" at Wall Street Zen - MarketBeat
Aug Highlights: Can Taysha Gene Therapies Inc stock rebound after recent weaknessIPO Watch & Precise Buy Zone Tips - moha.gov.vn
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 4.8%What's Next? - MarketBeat
Breakthrough And Pullback | 3 Stocks Deserve Close Attention: AXSM, TSHA And KALV - Sahm
Taysha Gene Therapies, Inc. (TSHA)’s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+ - MSN
Rice Hall James & Associates LLC Buys New Holdings in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap UpHere's Why - MarketBeat
Taysha Gene Therapies stock hits 52-week high at $5.98 By Investing.com - Investing.com Nigeria
Taysha Gene Therapies stock hits 52-week high at $5.98 - Investing.com
Taysha Gene Therapies (NASDAQ:TSHA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Does Taysha Gene Therapies Still Offer Value After a 196.8% Year to Date Surge? - Yahoo Finance
Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? - Yahoo Finance
Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades - Yahoo Finance
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program - Insider Monkey
Taysha Gene Therapies Earnings Notes - Trefis
Is Taysha Gene Therapies Inc. stock recession proofQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - Улправда
How analysts rate Taysha Gene Therapies Inc. stock todayBull Run & Weekly Stock Breakout Alerts - Улправда
Earnings Report: Is Taysha Gene Therapies Inc. stock recession proofWeekly Stock Analysis & Risk Controlled Stock Alerts - Улправда
Breakouts Watch: Is Taysha Gene Therapies Inc. stock recession proof2025 Trade Ideas & Free Fast Gain Swing Trade Alerts - Улправда
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Taysha Gene Therapies (NASDAQ:TSHA) Hits New 1-Year HighTime to Buy? - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
1,203,941 Shares in Taysha Gene Therapies, Inc. $TSHA Purchased by Stempoint Capital LP - MarketBeat
B Group Inc. Buys 545,000 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Taysha Gene Therapies stock hits 52-week high at 5.51 USD - Investing.com
Taysha Gene Therapies stock hits 52-week high at 5.51 USD By Investing.com - Investing.com South Africa
200,000 Shares in Taysha Gene Therapies, Inc. $TSHA Bought by Affinity Asset Advisors LLC - MarketBeat
Taysha Gene Therapies Grants Stock Options to New Employees as Part of Inducement Plan - Quiver Quantitative
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Can Taysha Gene Therapies Stock Hold Up When Markets Turn? - Trefis
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - MSN
Would You Still Hold Taysha Gene Therapies Stock If It Fell 30%? - Trefis
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Taysha Gene Therapies Inc-Aktie (TSHA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D |
Nov 28 '25 |
Option Exercise |
1.07 |
110,125 |
117,363 |
1,116,564 |
| Nagendran Sukumar | President and Head of R&D |
Dec 01 '25 |
Sale |
4.51 |
260,047 |
1,172,812 |
1,006,439 |
| Nagendran Sukumar | President and Head of R&D |
Nov 28 '25 |
Sale |
4.75 |
110,125 |
523,094 |
1,006,439 |
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):